Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia (OPTION-A)
Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE™ PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care during the same procedure.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The OPTION-A Study is an observational, prospective, single-arm, multi-center non-mandated post-market study. Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care. The objective(s) of the OPTION-A Study is to evaluate safety and effectiveness of catheter ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent implant of Left Atrial Appendage closure (LAAC) with the WATCHMAN™ LAA Closure device in a concomitant procedure.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
-
Beijing, Chine
- Xuanwu Hospital Capital Medical University
-
Beijing, Chine
- Beijing Anzhen Hospital of the Capital University of Medical Sciences
-
Chengdu, Chine
- Huaxi Hospital of Sichuan University
-
Chengdu, Chine
- The First Affiliated Hospital of Chengdu Medical College
-
Guangzhou, Chine
- The Third Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Chine
- Guangdong Nanfang Hospital
-
Guiyang, Chine
- The Affiliated Hospital of Guizhou Medical University
-
Hangzhou, Chine
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
-
Jinan, Chine
- QiLu Hospital of ShanDong University
-
Kunming, Chine
- First People's Hospital of Yunnan Province
-
Nantong, Chine
- Affiliated Hospital of Nantong University
-
Taiyuan, Chine
- Shanxi Cardiovascular Hospital
-
Zhuhai, Chine
- Zhuhai People's Hospital
-
Zigong, Chine
- Zigong First People's Hospital
-
-
Jiangsu
-
Suzhou, Jiangsu, Chine
- The First Affiliated Hospital of Soochow University
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
Hong Kong, Hong Kong
- Princess Margaret Hospital
-
Kowloon, Hong Kong
- Queen Elizabeth Hospital
-
-
-
-
-
Fukuoka-ken, Japon
- Kokura Memorial Hospital
-
Kanagawa, Japon
- Yokosuka Kyosai Hospital
-
Kawasaki, Japon
- Kawasaki Saiwai Hospital
-
Meguro-ku, Japon
- Toho University Ohashi Medical Center
-
Osaka, Japon
- Osaka Keisatsu Hospital
-
Yokohama, Japon
- Yokohama city minato Red Cross Hospital
-
-
Kanagawa
-
Kamakura-shi, Kanagawa, Japon
- Shonan Kamakura General Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japon
- Sendai Kousei Hospital
-
-
Okayama Kurashiki-shi
-
Kurashiki-shi, Okayama Kurashiki-shi, Japon
- Kurashiki Central Hospital
-
-
Saitama
-
Saitama, Saitama, Japon
- Saitama Red Cross Hospital
-
-
Tokyo
-
Fuchu-shi, Tokyo, Japon
- Sakakibara Heart Institute, Sakakibara Heart Foundation
-
-
-
-
-
Kuala Lumpur, Malaisie
- Institute Jantung Negara
-
Kuching, Malaisie
- Pusat Jantung Sarawak
-
-
-
-
-
Singapore, Singapour
- Asian Heart and Vascular Centre
-
-
-
-
-
Taichung, Taïwan
- China Medical University Hospital
-
Taichung, Taïwan
- Taichung Veterans General Hospital
-
Taipei, Taïwan
- National Taiwan University Hospital
-
Taipei, Taïwan
- Taipei Veterans General Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Subjects enrolled in the OPTION-A study will be clinically indicated for an Atrial Fibrillation ablation procedure utilizing the FARAPULSE PFA System as well as implantation of the WATCHMAN device per physician's medical judgement, and according to the hospitals' standard of care during the same procedure. The subjects selected for participation in the study will be from the investigator's general patient population. The investigator or designee has the responsibility for screening all potential subjects and selecting those who meet study eligibility criteria.
La description
Inclusion Criteria:
- Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN for LAAC, per physician medical judgement and as per hospitals' standard of care.
- Subjects who are willing and able to provide informed consent.
- Subjects who are willing and able to participate in all testing associated with this clinical study at an approved clinical investigational center.
- Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subjects who underwent prior AF ablation procedure.
- Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
- Already surgically closed or otherwise excluded LAA.
- The LAA anatomy does not accommodate a Closure Device.
- Known or suspected atrial myxoma.
- Presence of intracardiac thrombus.
- Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an ASD/PFO device.
- Subjects with a presence of a mechanical valve prosthesis in any position.
- Subjects with a myocardial infarction within 30 days prior to enrollment.
- Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 90 days prior to enrollment.
- Any planned electrical cardioversion within 30 days following LAAC device implant.
- Subjects with a known inability to obtain vascular access.
- Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy), active conditions (e.g. infection, bleeding disorder, unstable angina) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present*.
- Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina) are present.
- Subjects with any contraindications to short term use of anticoagulation therapy, or aspirin for conditions different from atrial fibrillation.
- Subjects who are pregnant or planning to be pregnant.
- Subjects with a life expectancy of ≤ 1 year per investigator's opinion.
- Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Treatment Subjects
A subject is considered enrolled once an approved informed consent form has been signed and dated. Enrolled Subjects will undergo AF ablation procedure with the FARAPULSE PFA System, followed by WATCHMAN implant during the same procedure. |
The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath. The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Periprocedural or procedure-related Composite Serious Adverse Events will be assessed
Délai: 30 days post index procedure
|
The primary safety endpoint (PSE) is the proportion of subjects with one or more of the periprocedural device or procedure-related Composite Serious Adverse Events (CSAEs) assessed at 30 days following the Index Procedure. |
30 days post index procedure
|
|
Acute Treatment Success will be assessed
Délai: between index procedure and 30 days post index procedure
|
The primary effectiveness endpoint (PEE) is the proportion of subjects with Acute Treatment Success assessed among those receiving ≥1 PFA application and who have a WATCHMAN attempted or implanted. |
between index procedure and 30 days post index procedure
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Device or procedure-related Composite Serious Adverse Events (CSAEs) assessed
Délai: 1 year post index procedure
|
Device or procedure-related Composite Serious Adverse Events (CSAEs) assessed at 360 days following the Index Procedure |
1 year post index procedure
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PF316
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .